Author: Martin Brekke-Jenssen
-
Coremine Medical Used in New Research
Coremine Medical used in new research Amazing breakthroughs have been achieved this year through the use of Coremine Medical. Three studies have harnessed the power of Coremine Medical to further their research, resulting in new and exciting discoveries. One study, by Discon Sheeja Malar et al., explored the links between Alzheimer’s Disease (AD), Diabetes (DM),…
-
New Milestone for Coremine Medical
New Milestone for Coremine Medical Hey there! We are thrilled to announce that our Coremine Medical platform has reached an incredible milestone of over 10,000 users! We want to express our sincere gratitude to all the users who have chosen to trust us with their medical information needs. We are committed to providing top-notch solutions…
-
We are now on YouTube!
We are now on youtube! We have now created our own YouTube channel and just posted a new video introduction to Coremine Medical! The video explains how you can use Coremine Medical for biomedical research. Together with this video we have also published a series of shorter tutorial videos on how to do various tasks…
-
AntiSeptic – New Eurostars project awarded July 2022
AntiSeptic – New Eurostars project awarded July 2022 PubGene was awarded a new Eurostars project with start date July 2022 together with Da Vinci laboratory solution B.V., Erasmus MC and Evosep Aps. In this project we will develop a technology platform for rapid identification of causative bacterial species in bloodstream infections (BSI/sepcis) by identifying their…
-
The ‘GlioPhos’ project
The ‘GlioPhos’ project Glioblastoma is a highly heterogeneous tumour and patients with this disease have a poor prognosis. Partly because the tumour infiltrates the surrounding brain tissue, surgical removal of the tumour is often incomplete, so that it is usually necessary to give these patients an adjuvant treatment after surgery. In general, these treatments are…
-
Dr. Jimita Toraskar Interviewed By The Future Of Health.Care Group
Dr Jimita Toraskar interviewed by the Future of Health Care Group The futureofhealth.care is an online discussion platform for healthcare professionals. It identifies white space in the market so that promising start-up and healthcare industry can get actionable and early insights to make better decisions. Recently, the future of health.care group interviewed Dr. Jimita Toraskar,…
-
Why Google, When You Can Coremine – Lecture by Jimita Toraskar
Why Google, When You Can Coremine – Lecture by Jimita Toraskar Dr. Jimita Toraskar from PubGene AS was invited to participate in the International Lecture Series organized by Dr. Bhanuben Nanavati College of Pharmacy in Mumbai, India. As a part of this initiative, Dr. Jimita Toraskar (Scientist at PubGene AS) delivered a hands-on session titled,…
-
Pubgene’s digital health COREMINE Vitae™ obtained CE-mark
PubGene’s digital health platform for personalised medicine, Coremine Vitae, obtained the CE-mark Class I Medical Device, ensuring that it complies with all the relevant Essential Requirements of the Medical Devices Directive – 93/42/EEC MDD and subsequent amendments.
-
Pre-study on the use of COREMINE™ Medical AS decision support for Covid-19
Pre-study on the use of COREMINE™ Medical AS decision support for Covid-19 Innovation Norway – the State and the county authorities’ instrument for achieving value-creating business development – has allocated pre-project funds to PubGene to investigate how COREMINE Medical can be used to identify “state of art” information when unforeseen health challenges (such as Covid-19) emerge. The Covid-19 pandemic has shown…
-
PubGene received the Horizon 2020 Seal of Excellence
PubGene’s project proposal ‘Coremine Vitae: Realising the promise of precision medicine for cancer patients and their healthcare providers with biomedical intelligence reporting’ submitted for the European Innovation Council (EIC) Accelerator programme has received the Horizon 2020 Seal of Excellence, both at the January and the March cut-offs, confirming that the proposal passed all evaluation thresholds. Objectives for the…